Hiroshima University Hospital – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 31
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: H1C1673DA0DEN
Leaflet:

Download PDF Leaflet

Hiroshima University Hospital – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Hiroshima University Hospital – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Hiroshima University Hospital – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Hiroshima University Hospital human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Hiroshima University Hospital with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Hiroshima University Hospital’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Hiroshima University Hospital’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Hiroshima University Hospital in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Hiroshima University Hospital’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Hiroshima University Hospital.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Hiroshima University Hospital and identify potential opportunities in those areas.
Hiroshima University Hospital Snapshot
Key Information
Key Facts
Hiroshima University Hospital – Research and Development Overview
Key Therapeutic Areas
Hiroshima University Hospital – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Hiroshima University Hospital – Pipeline Products Glance
Hiroshima University Hospital – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Hiroshima University Hospital Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Hiroshima University Hospital – Drug Profiles
Entecavir + Branched-Chain Amino Acids
  Product Description
  Mechanism of Action
  R&D Progress
Suplatast Tosilate
  Product Description
  Mechanism of Action
  R&D Progress
Xelox + Bevacizumab
  Product Description
  Mechanism of Action
  R&D Progress
Nucleotide Analogues + HBIG + HB Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Paclitaxel + S-1
  Product Description
  Mechanism of Action
  R&D Progress
Peginterferon alfa-2b + Ribavirin + Pitavastatin
  Product Description
  Mechanism of Action
  R&D Progress
Recombinant Interferon Alfa-2b + 5-Fluorouracil
  Product Description
  Mechanism of Action
  R&D Progress
TS-1
  Product Description
  Mechanism of Action
  R&D Progress
TS-1 + Lentinan
  Product Description
  Mechanism of Action
  R&D Progress
Hiroshima University Hospital – Pipeline Analysis
Hiroshima University Hospital – Pipeline Products by Therapeutic Class
Hiroshima University Hospital Pipeline Products By Target
Hiroshima University Hospital – Pipeline Products by Route of Administration
Hiroshima University Hospital – Pipeline Products by Molecule Type
Hiroshima University Hospital – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 31

LIST OF TABLES

Hiroshima University Hospital – Pipeline by Therapy Area and Indication, 2010
Hiroshima University Hospital – Pipeline by Stage of Development, 2010
Hiroshima University Hospital – Monotherapy Products in Pipeline, 2010
Hiroshima University Hospital – Combination Treatment Modalities in Pipeline, 2010
Hiroshima University Hospital – Phase III, 2010
Hiroshima University Hospital - Phase II, 2010
Hiroshima University Hospital - Pipeline By Therapeutic Class, 2010
Hiroshima University Hospital - Pipeline By Target, 2010
Hiroshima University Hospital – Pipeline By Route of Administration, 2010
Hiroshima University Hospital – Pipeline By Molecule Type, 2010 30

LIST OF FIGURES

Hiroshima University Hospital – Pipeline by Therapy Area and Indication, 2010
Hiroshima University Hospital – Pipeline by Stage of Development, 2010
Hiroshima University Hospital – Monotherapy Products in Pipeline, 2010
Hiroshima University Hospital – Combination Treatment Modalities in Pipeline, 2010
Hiroshima University Hospital – Pipeline By Therapeutic Class, 2010
Hiroshima University Hospital - Pipeline By Target, 2010
Hiroshima University Hospital – Pipeline By Route of Administration, 2010
Hiroshima University Hospital – Pipeline By Molecule Type, 2010 30

Ask Your Question

Hiroshima University Hospital – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: